自2019年12月武汉首次出现新型冠状病毒肺炎（COVID-19），越来越多人被确诊，已经扩散到了中国各地和境外多个国家。由于尚没有特效药，很多已被批准的"老药"被用于COVID-19的临床治疗中。青蒿素是世界卫生组织推荐的一线抗疟药物，研究发现其还具有抗炎、免疫调节、抗肺纤维化、抗菌、抗病毒、心血管作用等多种药理作用。综述了青蒿素及其衍生物抗COVID-19相关的药理作用及其作用机制，以挖掘其潜在的药用价值，重点探讨了其用于治疗COVID-19的可行性，为发掘有效的治疗药物提供参考。

Since the initial cases of the Coronavirus Disease in 2019 (COVID-19) occurred in Wuhan in December 2019, more and more cases have been found and confirmed, not only in central China but also in other countries. Given there are still no effective drugs many approved "old drugs" are in clinical test for treating COVID-19 at present. Artemisinin, a first-line antimalarial drug recommended by WHO, has been validated to possess a variety of pharmacological effects, including, without limitation, antiinflammatory, immune regulation, anti-pulmonary fibrosis, antibacterial, antiviral and cardiovascular effects, and the like. In this paper, various pharmacological effects of Artemisinin and its derivatives have been summarized, with the emphasis on the mechanism of action, so as to explore its potential medicinal value, especially for treating COVID-19.

R285.6

国家科技重大专项"中医药优势领域的创新中药关键技术开发研究"（2017ZX09301005）；山东省重点研发计划"新型冠状病毒潜在药物临床评价研究"（2020SFXGFY07）